Estradiol TDS
Total Payments
$1.7M
Transactions
29
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.7M | 29 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 29 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multiple Site Study to Compare the Cumulative Skin Irritation and Sensitization Potential of a Test Product Transdermal System Compared to the Marketed Estradiol Transdermal System (DS320116) | Amneal Pharmaceuticals LLC | $1.2M | 0 |
| Open-Label, Single-Application, Two-Treatment, Two-Period, Crossover Pivotal Adhesion Study of One Test Formulation of Estradiol Film, Extended Release Transdermal 0.1 mg/24 hour (Amneal Pharmaceuticals) Compared to Minivelle (estradiol transdermal system) 0.1 mg/24 hour (Noven Pharmaceuticals,Inc.) in Healthy Post-Menopausal Female Subjects (38115) | Amneal Pharmaceuticals LLC | $413,810 | 0 |
Top Doctors Receiving Payments for Estradiol TDS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Newark, DE | $1.7M | 29 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 0
- Transactions 29
About Estradiol TDS
Estradiol TDS is a drug associated with $1.7M in payments to 0 healthcare providers, recorded across 29 transactions in the CMS Open Payments database. The primary manufacturer is Amneal Pharmaceuticals LLC.
Payment data is available from 2017 to 2017. In 2017, $1.7M was paid across 29 transactions to 0 doctors.
The most common payment nature for Estradiol TDS is "Unspecified" ($1.7M, 100.0% of total).
Estradiol TDS is associated with 2 research studies, including "A Multiple Site Study to Compare the Cumulative Skin Irritation and Sensitization Potential of a Test Product Transdermal System Compared to the Marketed Estradiol Transdermal System (DS320116)" ($1.2M).